Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTLNASDAQ:FWPAYNASDAQ:RLMDNASDAQ:TENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$6.43-10.7%$6.10$4.92▼$9.30$21.10M1.0323,284 shs14,135 shsFWPAYForward Pharma A/S$300.00$424.38$1.43▼$5.33$6M-42.677 shs11 shsRLMDRelmada Therapeutics$0.71+1.1%$0.51$0.24▼$4.47$23.50M0.65952,897 shs253,376 shsTENXTenax Therapeutics$6.11+7.2%$5.76$2.77▼$7.89$25.34M1.61159,777 shs36,650 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-10.63%-3.45%+16.49%+16.36%-21.78%FWPAYForward Pharma A/S0.00%0.00%0.00%0.00%0.00%RLMDRelmada Therapeutics+1.13%-14.33%+53.60%+139.22%-76.48%TENXTenax Therapeutics+7.19%+4.27%+3.74%-2.24%+94.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.1118 of 5 stars3.64.00.00.01.00.00.6FWPAYForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ARLMDRelmada Therapeutics4.805 of 5 stars3.15.00.04.43.34.21.3TENXTenax Therapeutics1.6495 of 5 stars3.60.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.20Buy$33.00413.22% UpsideFWPAYForward Pharma A/S 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.25Hold$5.00606.11% UpsideTENXTenax Therapeutics 3.25Buy$17.50186.42% UpsideCurrent Analyst Ratings BreakdownLatest FWPAY, TENX, ARTL, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/6/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.005/15/2025TENXTenax TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.004/28/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/2/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$4.12 per shareN/AFWPAYForward Pharma A/SN/AN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$2.84 per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$27.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.29M-$2.99N/AN/AN/AN/A-104.59%-94.06%8/12/2025 (Estimated)FWPAYForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/ARLMDRelmada Therapeutics-$98.79M-$2.51N/AN/AN/AN/A-129.80%-112.06%8/6/2025 (Estimated)TENXTenax Therapeutics-$7.71M-$2.48N/AN/AN/AN/A-46.00%-42.65%8/12/2025 (Estimated)Latest FWPAY, TENX, ARTL, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TENXTenax Therapeutics-$0.48-$0.28+$0.20-$0.28N/AN/A5/13/2025Q1 2025ARTLArtelo Biosciences-$0.78-$4.32-$3.54-$0.72N/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/A3/27/2025Q4 2024RLMDRelmada Therapeutics-$0.70-$0.62+$0.08-$0.62N/AN/A3/25/2025Q4 2024TENXTenax Therapeutics-$0.52-$0.18+$0.34-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/AFWPAYForward Pharma A/SN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A7.157.15FWPAYForward Pharma A/SN/AN/AN/ARLMDRelmada TherapeuticsN/A6.896.89TENXTenax TherapeuticsN/A38.9538.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%FWPAYForward Pharma A/S2.63%RLMDRelmada Therapeutics45.24%TENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%FWPAYForward Pharma A/S71.47%RLMDRelmada Therapeutics20.70%TENXTenax Therapeutics3.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences53.28 million3.20 millionNot OptionableFWPAYForward Pharma A/SN/A20,0007,000Not OptionableRLMDRelmada Therapeutics1033.19 million24.74 millionOptionableTENXTenax Therapeutics94.15 million3.28 millionNot OptionableFWPAY, TENX, ARTL, and RLMD HeadlinesRecent News About These CompaniesTenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comTenax Therapeutics Inc.May 9, 2025 | barrons.comTenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsApril 16, 2025 | seekingalpha.comTenax Therapeutics files to sell 4.14M shares of common stock for holdersApril 16, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTenax Therapeutics reports Q4 EPS (18c), consensus (43c)March 27, 2025 | markets.businessinsider.comTenax Therapeutics (TENX) Gets a Buy from William BlairMarch 27, 2025 | markets.businessinsider.comTenax Therapeutics: Q4 Earnings SnapshotMarch 25, 2025 | timesunion.comTenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | globenewswire.comTenax Therapeutics Inc TENXMarch 15, 2025 | morningstar.comRoth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)March 6, 2025 | markets.businessinsider.comTenax Therapeutics expands Phase 3 LEVEL program for TNX-103March 5, 2025 | markets.businessinsider.comTenax Therapeutics prices 378,346 shares at $6.04 in private placementMarch 5, 2025 | markets.businessinsider.comTenax Therapeutics Announces $25 Million Private PlacementMarch 5, 2025 | globenewswire.comTenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEFMarch 5, 2025 | globenewswire.comTenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare ConferenceMarch 3, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 31, 2025 | globenewswire.comTenax Therapeutics, Inc. Common Stock (TENX) Insider ActivityJanuary 28, 2025 | nasdaq.comTenax Therapeutics Appoints Gillian Andor Vice President, Clinical OperationsJanuary 22, 2025 | markets.businessinsider.com(TENX) Pivots Trading Plans and Risk ControlsJanuary 1, 2025 | news.stocktradersdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFWPAY, TENX, ARTL, and RLMD Company DescriptionsArtelo Biosciences NASDAQ:ARTL$6.43 -0.77 (-10.69%) Closing price 06/16/2025 03:59 PM EasternExtended Trading$6.42 0.00 (-0.08%) As of 06/16/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Forward Pharma A/S NASDAQ:FWPAYForward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark.Relmada Therapeutics NASDAQ:RLMD$0.71 +0.01 (+1.13%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.71 +0.01 (+0.83%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Tenax Therapeutics NASDAQ:TENX$6.11 +0.41 (+7.19%) Closing price 06/16/2025 03:59 PM EasternExtended Trading$6.28 +0.17 (+2.78%) As of 06/16/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
